Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy.
暂无分享,去创建一个
Merlin C. Thomas | Merlin C Thomas | G. Jerums | M. Cooper | T. Osicka | W. Burns | J. Forbes | L. Burrell | S. Grant | V. Thallas | G. Brammar | F. Lee | G. C. Brammar | M. Thomas | M. Cooper | Wendy C. Burns
[1] G. Jerums,et al. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat , 1995, Diabetologia.
[2] W. Graier,et al. Vascular targets of redox signalling in diabetes mellitus , 2002, Diabetologia.
[3] Maristela L Onozato,et al. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. , 2002, Kidney international.
[4] R. Cohen,et al. High glucose via peroxynitrite causes tyrosine nitration and inactivation of prostacyclin synthase that is associated with thromboxane/prostaglandin H(2) receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endothelial cells. , 2002, Diabetes.
[5] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.
[6] M. Cooper,et al. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension , 2001, Diabetologia.
[7] A. Schmidt,et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. , 2001, American journal of physiology. Endocrinology and metabolism.
[8] W. Hung,et al. Role of receptor for advanced glycation end‐product (RAGE) and the JAK/STAT‐signaling pathway in AGE‐induced collagen production in NRK‐49F cells , 2001, Journal of cellular biochemistry.
[9] G. Jerums,et al. Ramipril and aminoguanidine restore renal lysosomal processing in streptozotocin diabetic rats , 2001, Diabetologia.
[10] G. Jerums,et al. Renoprotective effects of a novel inhibitor of advanced glycation , 2001, Diabetologia.
[11] J. Egido,et al. ACE inhibitors and AT(1) receptor antagonists-beyond the haemodynamic effect. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[12] Y. Kaneda,et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage , 2000, Nature.
[13] M. Ganz,et al. AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. , 2000, American journal of physiology. Renal physiology.
[14] Bruce H. R. Wolffenbuttel,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.
[15] S. Yusuf,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[16] G. Jerums,et al. Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C. , 2000, Diabetes.
[17] A. Heidland,et al. Advanced Glycation End-Product Levels in Subtotally Nephrectomized Rats: Beneficial Effects of Angiotensin II Receptor 1 Antagonist Losartan , 1999, Mineral and Electrolyte Metabolism.
[18] F. Murad,et al. Nitrotyrosine formation with endotoxin-induced kidney injury detected by immunohistochemistry. , 1999, American journal of physiology. Renal physiology.
[19] T. Miyata,et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. , 1999, Journal of the American Society of Nephrology : JASN.
[20] Z. Makita,et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195 , 1999, Diabetologia.
[21] G. Jerums,et al. Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding. , 1999, Kidney international.
[22] A. Schmidt,et al. Sp1-binding Elements in the Promoter of RAGE Are Essential for Amphoterin-mediated Gene Expression in Cultured Neuroblastoma Cells* , 1998, The Journal of Biological Chemistry.
[23] W. Linz,et al. Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats. , 1997, Hypertension.
[24] S. Klahr,et al. Enalapril decreases nuclear factor κB activation in the kidney with ureteral obstruction: Rapid Communication , 1997 .
[25] G. Jerums,et al. Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats , 1997, Diabetologia.
[26] J. Malacara,et al. Novel analytical approach to monitoring advanced glycosylation end products in human serum with on-line spectrophotometric and spectrofluorometric detection in a flow system. , 1997, Clinical chemistry.
[27] G. King,et al. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. , 1997, The Journal of clinical investigation.
[28] Y. Wada,et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. , 1997, Kidney international.
[29] S. Klahr,et al. Rapid communication. Enalapril decreases nuclear factor kappa B activation in the kidney with ureteral obstruction. , 1997, Kidney international.
[30] N. Traverso,et al. Good glycaemic control reduces oxidation and glycation end-products in collagen of diabetic rats , 1996, Diabetologia.
[31] J S Beckman,et al. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. , 1996, The American journal of physiology.
[32] G. Jerums,et al. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. , 1996, Kidney international.
[33] B. Robinson,et al. Mitochondrial complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase. , 1996, The Journal of clinical investigation.
[34] D. Harrison,et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. , 1996, The Journal of clinical investigation.
[35] J. Sampson. The kidney in tuberous sclerosis: manifestations and molecular genetic mechanisms. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[36] H. Kaneto,et al. Oxidative stress caused by glycation of Cu,Zn-superoxide dismutase and its effects on intracellular components. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[37] W. Cefalu,et al. Glycohemoglobin measured by automated affinity HPLC correlates with both short-term and long-term antecedent glycemia. , 1994, Clinical chemistry.
[38] E. Friedman,et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure , 1994, The Lancet.
[39] J. Baynes,et al. Glycation, Glycoxidation, and Cross-Linking of Collagen by Glucose: Kinetics, Mechanisms, and Inhibition of Late Stages of the Maillard Reaction , 1994, Diabetes.
[40] Y. Zou,et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.
[41] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.
[42] G. Wolf,et al. Angiotensin II as a renal growth factor. , 1993, Journal of the American Society of Nephrology : JASN.
[43] M. Mcdaniel,et al. Prevention of Diabetic Vascular Dysfunction by Guanidines: Inhibition of Nitric Oxide Synthase Versus Advanced Glycation End-Product Formation , 1993, Diabetes.
[44] S. Wolff. Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. , 1993, British medical bulletin.
[45] G. Jerums,et al. Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat , 1991, Diabetes.
[46] J. Baynes. Role of Oxidative Stress in Development of Complications in Diabetes , 1991, Diabetes.
[47] A. Cerami,et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. , 1986, Science.
[48] B. Brenner,et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. , 1986, The Journal of clinical investigation.
[49] S. Hsu,et al. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[50] R. Buñag. Validation in awake rats of a tail-cuff method for measuring systolic pressure. , 1973, Journal of applied physiology.
[51] J. Hodge. Dehydrated Foods, Chemistry of Browning Reactions in Model Systems , 1953 .